Get started
Author

Hitoshi Sase

ORCID: 0009-0000-8305-1732
Observed ORCID: 0009-0000-8305-1732
OpenAlex ID: A5073599331
Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor
2023 · Mikimasa Tanada, Minoru Tamiya, et al. · Journal of the American Chemical Society · 197
Arkadia Induces Degradation of SnoN and c-Ski to Enhance Transforming Growth Factor-β Signaling
2007 · Yoshiko Nagano, Konstantinos J. Mavrakis, et al. · Journal of Biological Chemistry · 177
PDF
Validation of a New Methodology to Create Oral Drugs beyond the Rule of 5 for Intracellular Tough Targets
2023 · Atsushi Ohta, Mikimasa Tanada, et al. · Journal of the American Chemical Society · 121
The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor
2014 · Yoshito Nakanishi, Nukinori Akiyama, et al. · Molecular Cancer Therapeutics · 121
Ras signaling directs endothelial specification of VEGFR2+ vascular progenitor cells
2008 · Kyoko Kawasaki, Tetsuro Watabe, et al. · The Journal of Cell Biology · 50
PDF
VEGFR2-PLCγ1 axis is essential for endothelial specification of VEGFR2+ vascular progenitor cells
2009 · Hitoshi Sase, Tetsuro Watabe, et al. · Journal of Cell Science · 43
Identification of targets of Prox1 during in vitro vascular differentiation from embryonic stem cells: functional roles of HoxD8 in lymphangiogenesis
2009 · Kaori Harada, Tomoko Yamazaki, et al. · Journal of Cell Science · 35
ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor
2015 · Yoshito Nakanishi, Hideaki Mizuno, et al. · Molecular Cancer Therapeutics · 28
Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2 -Amplified Gastric Cancer
2018 · Hitoshi Sase, Yoshito Nakanishi, et al. · Molecular Cancer Therapeutics · 21
Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer
2018 · Hiroshi Tanaka, Hitoshi Sase, et al. · Molecular Cancer Therapeutics · 20
Structure-activity relationships of middle-size cyclic peptides, KRAS inhibitors derived from an mRNA display
2024 · Mirai Kage, Ryuji Hayashi, et al. · Bioorganic & Medicinal Chemistry · 15
Abstract 1654: Anti-tumor activity of orally-available cyclic peptide LUNA18 through direct RAS inhibition in RAS-altered tumors
2024 · Hitoshi Sase, Saki Michisaka, et al. · Cancer Research · 8
Antitumor Activity of Orally Available Cyclic Peptide LUNA18 through Direct Pan-RAS Inhibition across Diverse RAS Genetic Alterations
2026 · Hitoshi Sase, Saki Michisaka, et al. · Molecular Cancer Therapeutics · 3
Abstract 1664: Combination of LUNA18, a novel RAS inhibitor, with KRAS G12C inhibitors augments anti-tumor activity via inhibition of MAPK pathway reactivation
2024 · Saki Michisaka, Hitoshi Sase, et al. · Cancer Research · 3
Abstract 2729: FGFR genetic alterations as a potential predictor of the sensitivity to CH5183284/Debio 1347, a selective FGFR inhibitor with a novel chemical scaffold
2014 · Yoshito Nakanishi, Nukinori Akiyama, et al. · Cancer Research · 2
Abstract 5980: AUBE00: A novel cyclic peptide pan-KRAS inhibitor targeting KRAS-activated cancers including KRAS-mutant cancers and wild-type colorectal cancer
2026 · Kana Takei, Mayuki Ueda, et al. · Cancer Research
Supplementary Figures S1-S7 and Table from The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor
2023 · Yoshito Nakanishi, Nukinori Akiyama, et al.
Supplementary Materials and Methods from The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor
2023 · Yoshito Nakanishi, Nukinori Akiyama, et al.
Supplementary Tables S1 through S3 and Supplementary Figures S1 and S2 from ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor
2023 · Yoshito Nakanishi, Hideaki Mizuno, et al.
Table S1 from Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer
2023 · Hiroshi Tanaka, Hitoshi Sase, et al.
Figures S1-5 & Tables S2-5 from Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer
2023 · Hiroshi Tanaka, Hitoshi Sase, et al.
Data from Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer
2023 · Hiroshi Tanaka, Hitoshi Sase, et al.
Data from Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer
2023 · Hitoshi Sase, Yoshito Nakanishi, et al.
Table S1 from Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer
2023 · Hitoshi Sase, Yoshito Nakanishi, et al.
Figure S5 from Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer
2023 · Hitoshi Sase, Yoshito Nakanishi, et al.
PDF
Works count: 48
Citation count: 836
H-index: 11
I10-index: 11
Year
Topic
Type